Status:
UNKNOWN
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18-90 years
Brief Summary
The purpose of this study is to determine whether monitoring of levels of Serological Markers ProGRP, CgA, NSE and Pyruvate Kinase M2 are effective in the Evaluation of Diagnosis, Monitoring Therapeut...
Detailed Description
Assessment of the anatomical spread and disease progression in neuroendocrine tumor patients has become an essential part of disease management, but sometimes in many patients difficult to be measured...
Eligibility Criteria
Inclusion
- The patients at diagnosis of neuroendocrine tumors before therapy will be approached to participate in the study.
- Older then 18 years old
- Patients who agree to participate will receive a detailed explanation and sign an informed consent form.
Exclusion
- Pregnant women
- Coexistence of another primary malignant tumor other then neuroendocrine tumors
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00851604
Start Date
March 1 2009
End Date
January 1 2011
Last Update
June 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120